<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-EGFR antibodies show benefits for some K-ras <z:mp ids='MP_0002169'>wild-type</z:mp> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Addinganti -VEGF monoclonal antibodies to stateof- the-art adjuvant chemotherapy for stage II or III <z:hpo ids='HP_0003003'>colon cancer</z:hpo> does not improve disease-free survival </plain></SENT>
<SENT sid="2" pm="."><plain>Bevacizumab shows an additive effect for FOLFOX/FOLFIRI therapy as a first-line chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Anti-EGFR therapy has limited adaptation as a first-line chemotherapy based on current evidence and adverse events </plain></SENT>
<SENT sid="4" pm="."><plain>When the disease is greatly influenced by <z:mp ids='MP_0010537'>tumor regression</z:mp> or has high risk with bevacizumab, anti-EGFR therapy may be used as first-line chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Anti-EGFR therapy is recommended as second- or third-line chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>FOLFIRI therapy is recommended as a second-line therapy and IRI+ Cmab therapy is recommended as a third-line therapy in cases when it is possible to treat usingthree or higher lines </plain></SENT>
<SENT sid="7" pm="."><plain>Supportive care is especially important to improve the treatment outcome </plain></SENT>
</text></document>